Enrolling Studies
Alopecia
Androgenetic Alopecia
Protocol ID
250-13951-304
Indication
Male Pattern Baldness
Requirement
- A male between the ages of 18-65
- Experiencing signs of pattern hair loss, such as receding hairline, thinning at the temples, and/or thinning on the crown
- Current hair length is at least 1/4"
Female Hair Loss (Alopecia)
Protocol ID
250-13951-306
Indication
Female Hair Loss
Requirement
- Be in good general health
- Female 18-65
- Have normal liver and kidney function.
- Maintain at least 1/4-inch hair length during the study with the same hairstyle, hair length, and hair color throughout.
Enrollment Open
Atopic Dermatitis (Eczema)
Moderate to Severe Atopic Dermatitis (Enveda)
Protocol ID
ENV-294
Indication
Atopic Dermatitis / Eczema
Requirement
- Are 18 to 75 years old
- Have experienced recurring eczema for at least 12 months
- Poor response to or an inability to tolerate eczema creams in the past 6 months
- Poor response to eczema pills in the past 12 months
- Use a plain, fragrance-free moisturizer at least once daily
Enrollment Open
Atopic Dermatitis
Protocol ID
NCT06389136
Indication
Atopic Dermatitis / Eczema
Requirement
- Are between 18 and 63 years old
- Eczema for at least 3 years
- Currently using dupilumab (≥4 months) with poor control
- Moderate to severe eczema with frequent itching
- Rash covering ~10% or more of body
- Able to use moisturizer twice daily and attend clinic visits in Birmingham
Enrollment Open
Moderate to Severe Atopic Dermatitis (BROADEN2)
Protocol ID
KT621-AD-201
Indication
Atopic Dermatitis / Eczema
Requirement
- Are between 18 and 75 years old
- Have had atopic dermatitis (eczema) for at least 3 years
- Still experience flares or symptoms despite using other treatments
- Are willing to apply moisturizer twice daily during the study
Enrollment Open
Pediatric Eczema / Atopic Dermatitis
Protocol ID
B7451031Â
Indication
Atopic Dermatitis / Eczema
Requirement
- Are between 6 and 11 years old
- Weigh at least 33 lbs (15 kg)
- Were diagnosed with atopic dermatitis at least 6 months ago
- Currently have moderate-to-severe symptoms
- Have not had good results from topical medications
Enrollment Open
Moderate to Severe AD
Protocol ID
KT621-AD-102
Indication
Atopic Dermatitis
Requirement
- All People 19-55
- Have Chronic Atopic Dermatitis/Eczema for over a year
- Other medications aren’t helping
Enrollment Open
Mild to Moderate AD
Protocol ID
HY209-AD-02
Indication
Mild to Moderate Atopic Dermatitis
Requirement
- Men 19+
- Atopic Dermatitis/Eczema
- Other Medications don’t seem to be working
Enrollment Open
Child Atopic Dermatitis
Protocol ID
ARQ-151-218Â
Indication
Mild to moderate AD > 3% BSA including scalp and non-scalp
Requirement
- Children (3 months – 24 months)
- Atopic Dermatitis/Eczema
Enrollment Open
Chameleon Atopic Dermatitis
Protocol ID
CPI-818-003
Indication
Atopic Dermatitis
Requirement
- Be 18 years or older
- Have diagnosed atopic dermatitis
- Not responded well to many other types of treatment
- Your Eczema/Atopic Dermatitis is moderate to severe
Enrollment Open
Atopic Dermatitis
Protocol ID
AP43CP03
Indication
Atopic Dermatitis
Requirement
- Are 19–75 years of age
- Have experienced chronic (long-term) atopic dermatitis for at least 1 year
- Are not responding to current treatment
Enrollment Open
Chronic Pruritus
Chronic Pruritus
Protocol ID
SPR207913
Indication
Chronic Pruritus from Unknown Origin
Requirement
- You are 18 years or older
- You have had ongoing itching (pruritus) on otherwise normal-looking skin (except for dryness or scratching) for at least 6 months
- The cause of your itching is unknown—not clearly linked to another condition or medication
- The itching affects at least 4 areas of your body, such as your arms, legs, chest, or back
- Past treatments have not provided enough relief for your itching
Enrollment Open
Hidradenitis Suppurativa (HS)
Moderate to Severe HS
Protocol ID
M23-698
Indication
Moderate to severe HS. Rinvoq (upadacitinib) is a selective and reversible JAK inhibitor
Enrollment Open
Hidradenitis Suppurativa
Protocol ID
INCBO18424-325
Indication
Hidradenitis Suppurativa (HS)
Enrollment Open
Plaque Psoriasis
Plaque Psoriasis
Protocol ID
VY2024-03
Indication
Plaque Psoriasis
Requirement
- You must be 18-75 old
- Diagnosed with severe to moderate psoriasis
- Generally Healthy
- Not enrolled in another trial
- Must be able to comply with study procedures
Enrollment Open
Mild to moderate Plaque Psoriasis
Protocol ID
77242113PSO3006
Indication
Mild to moderate Plaque Psoriasis in Adolescents and Adults
Requirement
- Be 12 years of age or older
- Have been diagnosed with moderate to severe psoriasis for at least 6 months prior to beginning this study
Enrollment Open
Prurigo Nodularis
Prurigo Nodularis
Protocol ID
CDX0159-10
Indication
Prurigo Nodularis
Requirement
- Over 18years old
- Have had this painful condition for over 6 months
- Found that other medications don’t seem to work
Enrollment Open
Prurigo Nodularis
Protocol ID
INCB-54707-305
Indication
Prurigo Nodularis
Requirement
- You must be 18-75 old
- Have been diagnosed with PN for at least 3 months
- Are not pregnant (Women of childbearing potential must agree to use effective contraception)
- Meet other health criteria reviewed by the study team
Enrollment Open
Urticaria (Hives)
Embarq Hives
Protocol ID
CDX0159-16
Indication
Hives
Requirement
- Are 18 years or older
- Have been diagnosed with ColdU or SD for at least 3 months
- Continue to have symptoms despite taking daily antihistamines
- Have been on a stable antihistamine dose for at least 4 weeks
- Are willing to complete a daily symptom diary
Enrollment Open
Chronic Spontaneous Urticaria Study / Hives Caused by Touch or Cold
Protocol ID
EVO756-CIU001
Indication
Moderate to severe HS. Rinvoq (upadacitinib) is a selective and reversible JAK inhibitor
Requirement
- Are at least 18 years old
- Diagnosed with Chronic Inducible Urticaria for at least 3 months
- Get hives from touch, cold or scratching
Enrollment Open
Inducible Urticaria (Chronic Hives)
Protocol ID
CDX0159-12
Indication
Chronic Hives (CSU)
Requirement
- Be at least 18 years old
- Your hives last 6 weeks or longer
- Other treatments aren’t really helping
Enrollment Open
Chronic Spontaneous Urticaria (Hives)
Protocol ID
CDX0159-15
Indication
Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Requirement
- Are at least 18 years old
- Have been diagnosed with chronic urticaria for at least 6 months
- Have had at least one unsuccessful treatment for urticaria, resulting in ongoing urticaria symptoms, or
- Suffering from urticaria and itching for at least 8 consecutive weeks despite taking antihistamines or omalizumab
Enrollment Open
Meet Our Principal Investigator
Dr. Groysman is a Board-Certified Dermatologist and the founder and Medical Director of Cahaba Dermatology & Skin Health Center. Specializing in medical, surgical, cosmetic and laser dermatology, she is an experienced leader of medical teams treating a wide range of skin conditions, including mucosal disorders, rosacea and dermatologic disease of pregnancy. Dr. Groysman currently serves as a Clinical Assistant Professor of Dermatology at the University of Alabama Birmingham. We are proud to have her as our principal investigator.